Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk Read More
Agendia’s MammaPrint Now Included in Blue Shield of California Coverage for Breast Cancer Patients
IRVINE, CA and AMSTERDAM – 1 June 2017 – Agendia, Read More
Agendia’s MammaPrint Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands
IRVINE, CA and AMSTERDAM – 2 May 2017 – Agendia, Read More
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM – 12 April 2017 – Agendia, Read More
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrint® is the first and only multigene test to receive Read More
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint Read More
Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award
Significant clinical benefit of Agendia’s MammaPrint® test and other advances Read More
New Data Shows that MammaPrint Substantially Impacts how Breast Cancer Patients in Germany are Treated
PRIMe trial included 452 women at 27 centers in Germany, Read More
Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint and BluePrint in Individualizing Treatment for Breast Cancer Patients
Long-term follow-up of early-stage breast cancer patients shows significant difference Read More
Agendia Responds to IQWiG Assessment for Reimbursement of Gene Expression-based Breast Cancer Recurrence Tests
IRVINE, CA and AMSTERDAM, 5 December 2016 – Agendia, Inc., Read More
